GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene Biotek Ltd (BOM:526139) » Definitions » Buyback Yield %

Transgene Biotek (BOM:526139) Buyback Yield % : 0.00 (As of May. 02, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Transgene Biotek Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Transgene Biotek's current buyback yield was 0.00%.


Transgene Biotek Buyback Yield % Historical Data

The historical data trend for Transgene Biotek's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Biotek Buyback Yield % Chart

Transgene Biotek Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Transgene Biotek Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Transgene Biotek's Buyback Yield %

For the Biotechnology subindustry, Transgene Biotek's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene Biotek's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Buyback Yield % falls into.


;
;

Transgene Biotek Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Transgene Biotek's Buyback Yield for the fiscal year that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 616.7678
=0.00%

Transgene Biotek's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 517.5091
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Transgene Biotek Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Transgene Biotek's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene Biotek Business Description

Traded in Other Exchanges
N/A
Address
Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.

Transgene Biotek Headlines

No Headlines